David Mehalick - 27 Jan 2023 Form 4 Insider Report for Coeptis Therapeutics Holdings, Inc. (COEP)

Role
CEO and President, Director, 10%+ Owner
Signature
/s/ David Mehalick
Issuer symbol
COEP
Transactions as of
27 Jan 2023
Net transactions value
$0
Form type
4
Filing time
31 Jan 2023, 09:59:15 UTC
Previous filing
07 Nov 2022
Next filing
11 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COEP Non-qualified Stock Options (right to buy) Award +375,000 375,000 27 Jan 2023 Common Stock 375,000 $1.60 Direct F1, F3, F5, F7, F9
transaction COEP Incentive Stock Options (right to buy) Award +250,000 250,000 27 Jan 2023 Common Stock 250,000 $1.76 Direct F2, F4, F6, F8, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 27, 2023, the reporting person received a grant of 375,000 stock options, as non-qualified options, under the 2022 equity incentive plan.
F2 On January 27, 2023, the reporting person received a grant of 250,000 incentive stock options, under the 2022 equity incentive plan.
F3 Options will vest over 4 years, with the first 25% vesting on 12/31/23, and the balance vesting in equal quarterly installments over the succeeding three years, with the final options vesting on 12/31/26.
F4 Options will vest over 4 years, with the first 25% vesting on 12/31/23, and the balance vesting in equal quarterly installments over the succeeding three years, with the final options vesting on 12/31/26.
F5 The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Global Market on the day of grant.
F6 The exercise price is equal to 110% of the FMV of the shares on the day of grant.
F7 Expiration date is ten years from the day of grant
F8 Expiration date is five years from the day of grant, as the reporting person is a 10% owner and the options are incentive stock options.
F9 Following the exercise of options under both reported transactions, the reporting person will have a total of 625,000 derivative securities beneficially owned.
F10 Following the exercise of options under both reported transactions, the reporting person will have a total of 625,000 derivative securities beneficially owned.